The Molecular Genetics of Laryngeal Cancer

Otolaryngologic Clinics of North America

Volumn 41, Issue 4, 2008, Pages 657-672

  Loyo, Myriam ^a   Pai, Sara I ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; CISPLATIN; ERLOTINIB; GEFITINIB; GEMCITABINE; INTERLEUKIN 12; INTERLEUKIN 2; PICIBANIL; PROTEIN TYROSINE KINASE INHIBITOR; THYMOSTIMULIN;

CANCER INCIDENCE; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DISEASE COURSE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG RECEPTOR BINDING; EPIGENETICS; FATIGUE; GENETIC SUSCEPTIBILITY; HEAD AND NECK CARCINOMA; HUMAN; IMMUNE RESPONSE; LARYNX CANCER; LARYNX CARCINOMA; LYMPH NODE METASTASIS; MOLECULAR BIOLOGY; MOLECULAR GENETICS; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; PATIENT COMPLIANCE; PROTEIN EXPRESSION; QUALITY OF LIFE; RASH; REVIEW; SQUAMOUS CELL CARCINOMA; UNITED STATES; VOMITING;

CARCINOMA, SQUAMOUS CELL; CELL TRANSFORMATION, NEOPLASTIC; DNA MUTATIONAL ANALYSIS; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; LARYNGEAL NEOPLASMS; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; TUMOR ESCAPE;

EID: 44949123698     PISSN: 00306665     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.otc.2008.01.019     Document Type: Review

References (89)

1. Ries LAG, Melbert D, Krapcho M, et al, editors. SEER cancer statistics review, 1975-2004. Bethesda (MD): National Cancer Institute. Available at: http://seer.cancer.gov/csr/1975_2004/. based on November 2006 SEER data submission, posted to the SEER web site, 2007.
2. Almadori G., Bussu F., Cadoni G., et al. Molecular markers in laryngeal squamous cell carcinoma: towards an integrated clinicobiological approach. Eur J Cancer 41 (2005) 683-693
3. Gao X., Fisher S.G., Mohideen N., et al. Second primary cancers in patients with laryngeal cancer: a population-based study. Int J Radiat Oncol Biol Phys 56 (2003) 427-435
4. Hashibe M., Brennan P., Benhamou S., et al. Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. J Natl Cancer Inst 99 (2007) 777-789
5. Ha P.K., and Califano III J.A. The molecular biology of laryngeal cancer. Otolaryngol Clin North Am 35 (2002) 993-1012
6. Ho T., Wei Q., and Sturgis E.M. Epidemiology of carcinogen metabolism genes and risk of squamous cell carcinoma of the head and neck. Head Neck 29 (2007) 682-699
7. D'Souza G., Kreimer A.R., Viscidi R., et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 356 (2007) 1944-1956
8. Kreimer A.R., Clifford G.M., Boyle P., et al. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 14 (2005) 467-475
9. Ragin C.C., Modugno F., and Gollin S.M. The epidemiology and risk factors of head and neck cancer: a focus on human papillomavirus. J Dent Res 86 (2007) 104-114
10. Manjarrez M.E., Ocadiz R., Valle L., et al. Detection of human papillomavirus and relevant tumor suppressors and oncoproteins in laryngeal tumors. Clin Cancer Res 12 (2006) 6946-6951
11. Hobbs C.G., Sterne J.A., Bailey M., et al. Human papillomavirus and head and neck cancer: a systematic review and meta-analysis. Clin Otolaryngol 31 (2006) 259-266
12. Wiatrak B.J., Wiatrak D.W., Broker T.R., et al. Recurrent respiratory papillomatosis: a longitudinal study comparing severity associated with human papilloma viral types 6 and 11 and other risk factors in a large pediatric population. Laryngoscope 114 (2004) 1-23
13. Lele S.M., Pou A.M., Ventura K., et al. Molecular events in the progression of recurrent respiratory papillomatosis to carcinoma. Arch Pathol Lab Med 126 (2002) 1184-1188
14. Rady P.L., Schnadig V.J., Weiss R., et al. Malignant transformation of recurrent respiratory papillomatosis associated with integrated human papillomavirus type 11 DNA and mutation of p53. Laryngoscope 108 (1998) 735-740
15. Knudson Jr. A.G. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68 (1971) 820-823
16. Fearon E.R., and Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1 (1990) 759-767
17. Califano J., van der Riet P., Westra W., et al. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 56 (1996) 2488-2492
18. Gollin S.M. Chromosomal alterations in squamous cell carcinomas of the head and neck: window to the biology of disease. Head Neck 23 (2001) 238-253
19. Carey T.E., Van Dyke D.L., and Worsham M.J. Nonrandom chromosome aberrations and clonal populations in head and neck cancer. Anticancer Res 13 (1993) 2561-2567
20. Jin Y., Mertens F., Mandahl N., et al. Chromosome abnormalities in eighty-three head and neck squamous cell carcinomas: influence of culture conditions on karyotypic pattern. Cancer Res 53 (1993) 2140-2146
21. Jin Y., and Mertens F. Chromosome abnormalities in oral squamous cell carcinomas. Eur J Cancer B Oral Oncol 29 (1993) 257-263
22. Rosin M.P., Cheng X., Poh C., et al. Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin Cancer Res 6 (2000) 357-362
23. Bosch F.X., Ritter D., Enders C., et al. Head and neck tumor sites differ in prevalence and spectrum of p53 alterations but these have limited prognostic value. Int J Cancer 111 (2004) 530-538
24. Wang Q., Han D., and Wang W. Adenovirus-mediated p53 gene therapy of human laryngeal cancer. Zhonghua Zhong Liu Za Zhi 20 (1998) 418-421
25. Qiu Z., Lao M., and Wu C. Co-transfer of human wild-type p53 and granulocyte-macrophage colony-stimulating factor genes via recombinant adenovirus induces apoptosis and enhances immunogenicity in laryngeal cancer cells. Cancer Lett 167 (2001) 25-32
26. Qiu Z.H., Wu C.T., Lao M.F., et al. Growth suppression and immunogenicity enhancement of hep-2 or primary laryngeal cancer cells by adenovirus-mediated co-transfer of human wild-type p53, granulocyte-macrophage colony-stimulating factor and B7-1 genes. Cancer Lett 182 (2002) 147-154
27. Reed A.L., Califano J., Cairns P., et al. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 56 (1996) 3630-3633
28. Akanuma D., Uzawa N., Yoshida M.A., et al. Inactivation patterns of the p16(INK4a) gene in oral squamous cell carcinoma cell lines. Oral Oncol 35 (1999) 476-483
29. Hasegawa M., Nelson H.H., Peters E., et al. Patterns of gene promoter methylation in squamous cell cancer of the head and neck. Oncogene 21 (2002) 4231-4236
30. Riese U., Dahse R., Fiedler W., et al. Tumor suppressor gene p16 (CDKN2A) mutation status and promoter inactivation in head and neck cancer. Int J Mol Med 4 (1999) 61-65
31. Ha P., and Califano J.A. Promoter methylation and inactivation of tumour-suppressor genes in oral squamous-cell carcinoma. Lancet Oncol 7 (2006) 77-82
32. Calmon M.F., Colombo J., Carvalho F., et al. Methylation profile of genes CDKN2A (p14 and p16), DAPK1, CDH1, and ADAM23 in head and neck cancer. Cancer Genet Cytogenet 173 (2007) 31-37
33. Temam S., Bénard J., Dugas C., et al. Molecular detection of early-stage laryngopharyngeal squamous cell carcinomas. Clin Cancer Res 11 (2005) 2547-2551
34. Smith I.M., Mydlarz W.K., Mithani S.K., et al. DNA global hypomethylation in squamous cell head and neck cancer associated with smoking, alcohol consumption and stage. Int J Cancer 121 (2007) 1724-1728
35. Dassonville O., Formento J.L., Francoual M., et al. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 11 (1993) 1873-1878
36. Kalyankrishna S., and Grandis J.R. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 24 (2006) 2666-2672
37. Santini J., Formento J.L., Francoual M., et al. Characterization, quantification, and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas. Head Neck 13 (1991) 132-139
38. Lothaire P., Azambuja E., Dequanter D., et al. Molecular markers of head and neck squamous cell carcinoma: promising signs in need of prospective evaluation. Head Neck 28 (2006) 256-269
39. O-Charoenrat P., Rhys-Evans P.H., Modjtahedi H., et al. The role of c-erbB receptors and ligands in head and neck squamous cell carcinoma. Oral Oncol 38 (2002) 627-640
40. Imai K., and Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 6 (2006) 714-727
41. Loeffler-Ragg J., Witsch-Baumgartner M., Tzankov A., et al. Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma. Eur J Cancer 42 (2006) 109-111
42. Demiral A.N., Sarioglu S., Birlik B., et al. Prognostic significance of EGF receptor expression in early glottic cancer. Auris Nasus Larynx 31 (2004) 417-424
43. Kawaguchi Y., Kono K., Mimura K., et al. Cetuximab induces antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma. Int J Cancer 120 (2007) 781-787
44. Trigo R., Hitt P., Koralewski E., et al. Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): results of a phase II study. J Clin Oncol 22 (2004) 5502 [Meeting abstracts]
45. Robert F., Ezekiel M.P., Spencer S.A., et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 19 (2001) 3234-3243
46. Burtness B., Goldwasser M.A., Flood W., et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 23 (2005) 8646-8654
47. Bonner J.A., Harari P.M., Giralt J., et al. Improved preservation of larynx with the addition of cetuximab to radiation for cancers of the larynx and hypopharynx. J Clin Oncol 23 (2005) 5533 [Meeting abstracts]
48. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 (2006) 567-578
49. Robert F., Blumenschein G., Herbst R.S., et al. Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. J Clin Oncol 23 (2005) 9089-9096
50. Shin D.M., Donato N.J., Perez-Soler R., et al. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res 7 (2001) 1204-1213
51. American Society of Clinical Oncology, Pfister D.G., Laurie S.A., et al. American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J Clin Oncol 24 (2006) 3693-3704
52. De La Garza G, Granados M, Aguilar JL, et al. Phase II clinical trial preliminary report: cetuximab, gemcitabine and simultaneous radiotherapy for locally advanced head and neck cancer: preliminary report. J Clin Oncol 2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2006;24:15502.
53. Cohen E.E. Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 24 (2006) 2659-2665
54. Siu L.L., Soulieres D., Chen E.X., et al. Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study. J Clin Oncol 25 (2007) 2178-2183
55. Matar P., Rojo F., Cassia R., et al. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clin Cancer Res 10 (2004) 6487-6501
56. Baselga J, Schoffski P, Rojo H, et al. A phase I pharmacokinetic (PK) and molecular pharmacodynamic (PD) study of the combination of two anti-EGFR therapies, the monoclonal antibody (MAb) cetuximab (C) and the tyrosine kinase inhibitor (TKI) gefitinib (G), in patients (pts) with advanced colorectal (CRC), head and neck (HNC) and non-small cell lung cancer (NSCLC). ASCO Annual Meeting Proceedings 2006;24:3006.
57. Prenzel N., Zwick E., Daub H., et al. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 402 (1999) 884-888
58. Cohen E.E., Lingen M.W., Martin L.E., et al. Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clin Cancer Res 11 (2005) 8105-8108
59. Nelson A.R., and Rothenberg M.L. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 18 (2000) 1135-1149
60. Kerrebijn J.D.F., Simons P.J., Tas M., et al. The effects of thymostimulin on immunological function in patients with head and neck cancer. Clin Otolaryngol 21 (1996) 455-462
61. Coussens L.M., and Werb Z. Matrix metalloproteinases and the development of cancer. Chem Biol 3 (1996) 895-904
62. Garraud O., Faucher A., Legrand E., et al. Impairment of monocyte functions in advanced head and neck cancer. Immunol Lett 18 (1988) 213-218
63. Muraki Y., Yoshioka C., Tateishi A., et al. Localization of Fas antigen in oral squamous cell carcinoma. Br J Oral Maxillofac Surg 37 (1999) 37-40
64. Peschos D., Damala C., Stefanou D., et al. Expression of matrix metalloproteinase-9 (gelatinase B) in benign, premalignant and malignant laryngeal lesions. Histol Histopathol 21 (2006) 603-608
65. Lee J.W., Soung Y.H., Kim S.Y., et al. Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin Cancer Res 11 (2005) 2879-2882
66. Liu W.W., Zeng Z.Y., Wu Q.L., et al. Overexpression of MMP-2 in laryngeal squamous cell carcinoma: a potential indicator for poor prognosis. Otolaryngol Head Neck Surg 132 (2005) 395-400
67. Smith B.D., Smith B.L., Carter D., et al. Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma. J Clin Oncol 18 (2000) 2046-2052
68. Kyzas P.A., Cunha I.W., Ioannidis P.A., et al. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis. Clin Cancer Res 11 (2005) 1434-1440
69. Hinojar-Gutierrez A., Fernandez-Contreras M.E., Gonzalez-Gonzalez R., et al. Intratumoral lymphatic vessels and VEGF-C expression are predictive factors of lymph node relapse in T1-T4 NO laryngopharyngeal squamous cell carcinoma. Ann Surg Oncol 14 (2007) 248-257
70. Letessier E.M., Sacchi M., Johnson J.T., et al. The absence of lymphoid suppressor cells in tumor-involved lymph nodes of patients with head and neck cancer. Cell Immunol 130 (1990) 446-458
71. Kong H.L., Hecht D., Song W., et al. Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted form of the extracellular domain of the flt-1 vascular endothelial growth factor receptor. Hum Gene Ther 9 (1998) 823-933
72. Whiteside T.L., Chikamatsu K., and Nagashima S. Antitumor effects of cytolytic T lymphocytes (CTL) and natural killer (NK) cells in head and neck cancer. Anticancer Res 16 (1996) 2357-2364
73. Vlock D.R. Immunobiologic aspects of head and neck cancer. Clinical and laboratory correlates. Hematol Oncol Clin North Am 5 (1991) 797-820
74. Hald J., Rasmussen N., and Claesson M.H. Tumour-infiltrating lymphocytes mediate lysis of autologous squamous cell carcinomas of the head and neck. Cancer Immunol Immunother 41 (1995) 243-250
75. Pries R., and Wollenberg B. Cytokines in head and neck cancer. Cytokine Growth Factor Rev 17 (2006) 141-146
76. Tas M.P., Simons P.J., Balm F.J., et al. Depressed monocyte polarization and clustering of dendritic cells in patients with head and neck cancer: in vitro restoration of this immunosuppression by thymic hormones. Cancer Immunol Immunother 36 (1993) 108-114
77. Westermarck J., and Kahari V.M. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 13 (1999) 781-792
78. Cameron D.J., and Stromberg B.V. The ability of macrophages from head and neck cancer patients to kill tumor cells. Effect of prostaglandin inhibitors on cytotoxicity. Cancer 54 (1984) 2403-2408
79. McCawley L.J., Crawford H.C., King L.E., et al. A protective role for matrix metalloproteinase-3 in squamous cell carcinoma. Cancer Res 64 (2004) 6965-6972
80. Kerrebijn J.D., Balm A.J., Freeman J.L., et al. Who is in control of the immune system in head and neck cancer?. Crit Rev Oncol Hematol 31 (1999) 31-53
81. Sundelin K., Jadner M., Norberg-Spaak L., et al. Metallothionein and Fas (CD95) are expressed in squamous cell carcinoma of the tongue. Eur J Cancer 33 (1997) 1860-1864
82. Kim J.W., Wieckowski E., Taylor D.D., et al. Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. Clin Cancer Res 11 (2005) 1010-1020
83. Airoldi M., De Stefani A., Marchionatti S., et al. Survival in patients with recurrent squamous cell head and neck carcinoma treated with bio-chemotherapy. Head Neck 23 (2001) 298-304
84. Cortesina G., De Stefani A., Galeazzi E., et al. Interleukin-2 injected around tumor-draining lymph nodes in head and neck cancer. Head Neck 13 (1991) 125-131
85. Bray D., Yu S.Z., Koprowski II H., et al. Combination nonviral interleukin 2 gene therapy and external-beam radiation therapy for head and neck cancer. Arch Otolaryngol Head Neck Surg 129 (2003) 618-622
86. Xian J., Yang H., Lin Y., et al. Combination nonviral murine interleukin 2 and interleukin 12 gene therapy and radiotherapy for head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 131 (2005) 1079-1085
87. Kimura Y., Tojima H., Fukase S., et al. Clinical evaluation of sizofilan as assistant immunotherapy in treatment of head and neck cancer. Acta Otolaryngol Suppl 511 (1994) 192-195
88. Fukazawa H., Ohashi Y., Sekiyama S., et al. Multidisciplinary treatment of head and neck cancer using BCG, OK-432, and GE-132 as biologic response modifiers. Head Neck 16 (1994) 30-38
89. Monji M., Senju S., Nakatsura T., et al. Head and neck cancer antigens recognized by the humoral immune system. Biochem Biophys Res Commun 294 (2002) 734-741